BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38372727)

  • 21. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
    Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
    EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Oaknin A; Gladieff L; Martínez-García J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Fariñas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcón J; Follana P; Romero I; Lebreton C; Pérez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall LM;
    Lancet; 2024 Jan; 403(10421):31-43. PubMed ID: 38048793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    Kang J; Zhang J; Tian Z; Xu Y; Li J; Li M
    PLoS One; 2024; 19(2):e0276318. PubMed ID: 38319920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study.
    Lu N; Jiang YF; Xia WX; Huang Y; Xie CM; Xu C; Ye YF; Liu GY; Bei WX; Ke LR; Li WZ; Zhang C; Wang X; Liu Q; Chen X; Chen ZX; Xie C; Liang H; Xiang YQ
    EClinicalMedicine; 2023 Aug; 62():102136. PubMed ID: 37593221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
    Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
    Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
    Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
    J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
    BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
    Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C
    Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
    Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ
    Lancet; 2017 Oct; 390(10103):1654-1663. PubMed ID: 28756902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
    Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
    J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
    Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab biosimilar candidate TAB008 compared to Avastin
    Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.